SCHEMBL3737101

SCHEMBL3737101

CC(C)Oc1ccc(-c2noc(CCCOc3ccccc3)n2)cc1Cl

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.69
LMNA P02545 4/20 0.69
MAPT P10636 4/20 0.69
TSHR P16473 3/20 0.69
TDP1 Q9NUW8 5/20 0.64
HTT P42858 1/20 0.56
MAP4K4 O95819 2/20 0.55
MINK1 Q8N4C8 2/20 0.55
PRKCD Q05655 1/20 0.55
MAPK1 P28482 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
NPC1 O15118 1/20 0.51
ALDH1A1 P00352 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HPGD P15428 1/20 0.51
S1PR1 P21453 6/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3744485 0.95 L3MBTL1 (0.61) L3MBTL1LMNAMAPTTSHRTDP1
SCHEMBL3737025 0.88 L3MBTL1 (0.67) L3MBTL1LMNAMAPTTSHRTDP1
SCHEMBL3743067 0.85 TDP1 (0.53) L3MBTL1LMNAMAPTTSHRTDP1
SCHEMBL3743601 0.84 TDP1 (0.52) L3MBTL1LMNAMAPTTSHRTDP1
SCHEMBL3753896 0.83 TDP1 (0.51) L3MBTL1LMNAMAPTTSHRTDP1
SCHEMBL3744456 0.83 MAP4K4 (0.53) L3MBTL1LMNAMAPTTSHRTDP1
SCHEMBL3749362 0.82 MAP4K4 (0.54) L3MBTL1LMNAMAPTTDP1HTT
SCHEMBL3747436 0.82 L3MBTL1 (0.57) L3MBTL1LMNATSHRTDP1MAP4K4
SCHEMBL3741627 0.82 MAP4K4 (0.53) L3MBTL1LMNAMAPTTSHRTDP1
SCHEMBL3742098 0.81 MAP4K4 (0.51) L3MBTL1LMNAMAPTTDP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834039-B2 Oxadiazole compounds ABBOTT LABORATORIES (US) 2010-11-16 US disclosed
US-7834039-B2 Oxadiazole compounds ABBOTT LABORATORIES (US) 2010-11-16 US disclosed
US-7834039-B2 Oxadiazole compounds ABBOTT LABORATORIES (US) 2010-11-16 US disclosed
EP-2109364-A1 NOVEL OXADIAZOLE COMPOUNDS Abbott Laboratories (US) 2009-10-21 EP disclosed
US-20080280876-A1 Novel oxadiazole compounds ABBVIE INC. 2008-11-13 US disclosed
US-20080280876-A1 Novel oxadiazole compounds ABBVIE INC. 2008-11-13 US disclosed
US-20080280876-A1 Novel oxadiazole compounds ABBVIE INC. 2008-11-13 US disclosed
WO-2008076356-A1 NOVEL OXADIAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280876-A1 Novel oxadiazole compounds S1PR3, S1PR1, S1PR2 L3MBTL1 3430/4885LMNA 4756/4885MAPT 4556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.